FIELT (First line Inhibitor of EGFR in Lung cancer Treatment) is a prospective academic study investigating the efficacy and tolerability of first-line treatment with erlotinib in newly diagnosed advanced adenocarcinoma of the lung carrying EGFR kinase domain mutations, as well as the feasibility of inserting genomic testing in a multicenter clinical setting (S1 Text). The gene discussed is EGFR; the disease is lung cancer.